Versant Capital Management’s Royalty Pharma RPRX Stock Holding History

Versant Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$41.2K	Buy	734 +6	+0.8%	+$312	﹤0.01%	1501
2026 Q1	$34.9K	Sell	728 -22	-3%	-$964	﹤0.01%	1462
2025 Q4	$29K	Sell	750 -1,836	-71%	-$70K	﹤0.01%	1405
2025 Q3	$91.2K	Buy	2,586 +2,058	+390%	+$74.5K	0.01%	751
2025 Q2	$19K	Buy	528 +47	+10%	+$1.56K	﹤0.01%	1563
2025 Q1	$15K	Buy	481 +361	+301%	+$11.4K	﹤0.01%	1504
2024 Q4	$3.06K	Sell	120 -754	-86%	-$20K	﹤0.01%	1949
2024 Q3	$24.7K	Sell	874 -189	-18%	-$5.24K	0.01%	734
2024 Q2	$28K	Buy	1,063 +1,043	+5,215%	+$28.9K	0.01%	587
2024 Q1	$607	Hold	20	–	–	﹤0.01%	1654
2023 Q4	$562	Buy	20 +10	+100%	+$275	﹤0.01%	1653
2023 Q3	$271	Buy	+10	New	+$297	﹤0.01%	1811

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Versant Capital Management's RPRX Position: Q2 2026 in Review

Versant Capital Management increased its Royalty Pharma (RPRX) stake by 0.82% in Q2 2026, buying an estimated $312 and bringing the position to 734 shares worth $41.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1501.

Versant Capital Management first reported a position in RPRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $91.2K in Q3 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Versant Capital Management held 734 shares of Royalty Pharma worth $41.2K as of Q2 2026.
Versant Capital Management bought 6 Royalty Pharma shares in Q2 2026, an estimated $312.
Royalty Pharma made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1501 holding.
Versant Capital Management first reported a position in Royalty Pharma in Q3 2023 and has held it in 12 quarters since.
Versant Capital Management's Royalty Pharma position peaked at $91.2K in Q3 2025.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.